Thromboembolic recurrence frequency analysis in patients with deep vein thrombosis of lower extremities.

• Main Authors: Sergyi Vasyliuk, Vitaliia Atamaniuk
• Format: Article
• Language: English
• Published: Towarzystwo Pomocy Doraźnej 2020-03-01
• Series: Critical Care Innovations
• Subjects: thrombosis; anticoagulation; therapy; warfarin; rivaroxaban
• Online Access: https://www.irdim.net/cci/3(1)1-8.html

INTRODUCTION: To estimate the incidence of thromboembolic recurrence in patients whose deep vein thrombosis (DVT) during the initial and long-term anticoagulation and after its termination was treated. MATERIAL AND METHODS: There were examined and treated 98 patients with deep vein thrombosis of various locations. Patients were observed during anticoagulation therapy (n=98) and after its perfor-mance (n=76) for between 7 and 120 months. Depending on the scheme of anticoagulation therapy patients were divided into three groups: the first group (n=32) received warfarin, the second group (n=34) – rivaroxaban, the third one (n=32) – dabigatran etexilate. RESULTS: In terms of initial and long-term anticoagulant therapy, regardless of the choice of treatment regimens, DVT recurrence or pulmonary embolism cases we have not observed. After the treatment, during the first year, recurrence of DVT was more frequent in patients of all groups. In patients of the first group their frequency was 15.38±7.08%, the second group – 8.7±5.88%, the third one – 3.7±3.63%, which did not differ significantly (p=0.33). In general, the overall observation period showed a recurrence rate among the patients of the first group was 10 cases, 4 cases in the second group, and three cases in the third group (p<0.05). There was no signifi-cant difference in the incidence of thrombosis recurrence was observed between patients taking rivaroxaban and dabigatran etexilate, whereas there was a significant difference between the first and third groups (p<0.05). CONCLUSIONS: Long-term anticoagulation with warfarin is the least predictable as for the risk of re-currence of DVT (p<0.05), when the application of Rivaroxaban and dabigatran etexilate showed no significant difference in the incidence of DVT recurrence. Patients with provoking persistent risk factors and non-triggering factors require continued anticoagulation therapy indefinitely, or until this risk factor has been eliminated.